The global Bone And Mineral Metabolism Disorders Treatment Market is prognosticated to secure a rising growth with the surging occurrence of metabolic disorders and chronic kidney diseases (CDKs). It is approximated that millions of Americans above the age of 50 years are suffering from osteoporosis while a closer count of the people could be at the risk of developing the bone disease. This could promote promising opportunities in the U.S. market for bone and mineral metabolism disorders treatment. Furthermore, a surging awareness about the management of such disorders among healthcare professionals and improved access to diagnosis are prophesied to unveil new avenues in the market. On the whole, the market is envisioned to showcase a steady growth during the forecast period.
The demand in the global bone and mineral metabolism disorders treatment market could be further strengthened by changes encouraged to cut down treatment costs. This is anticipated to be on account of the intensified competition between local and international companies. The dynamics of the market are expected to undergo favorable changes, owing to the availability of an expansive gamut of products in different strengths and forms. North America and Europe could be lucrative markets for bone and mineral metabolism disorders treatment in view of their potential to bear higher product costs. Asia Pacific, on the other hand, is projected to make its contribution to the global market while riding on the elevating incidences of metabolic diseases and stenting in children and profitable population dynamics.
Bone and mineral metabolism disorder is a collective term used to describe various conditions that make bones weak. Bone mineral metabolism maintains sufficient concentration of inorganic ions in blood serum. Progressive chronic kidney disease, especially end-stage renal disease (ESRD), is responsible for adverse changes in bone and mineral metabolism. Increase in serum parathyroid hormone levels due to fall in glomerular filtration rate is an indicator of bone disorder caused by chronic kidney disease. Reduction in kidney function leads to changes in bone mineral homeostasis and in levels of parathyroid hormone (PTH), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and fibroblast growth factor-23 (FGF-23). Disorders of mineral metabolism in chronic kidney disease (CKD) have been associated with higher mortality than anemia and inadequate dialysis. Increased prevalence of chronic kidney diseases, rising geriatric population, and changing lifestyles which lead to mineral and hormonal disturbances drive the bone and mineral metabolism disorders treatment market. However, high cost of the treatment and side effects of the medications hamper market growth.
Request to View Brochure of Report -
The bone and mineral metabolism disorders treatment market can be segmented based on type of disorder, type of medication used to prevent and treat bone and mineral disorders, and region. In terms of type of disorder, the market can be classified into osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica, adynamic bone disease, vascular calcification, and Pagets disease. Osteoporosis and vascular calcification are highly prevalent among the CKD population and are progressing rapidly. Medications are segmented based on type of disorder to be treated. For instance, treatment of osteoporosis involves prevention of fractures. Hence, the osteoporosis medications segment can be classified into drugs and nutrients used for primary prevention of fractures including calcium and vitamin D supplements, and hip protectors and hip pads to avoid hip damage due to fall. Drugs utilized to treat osteoporosis are categorized into antiresorptive drugs (to reduce bone loss) and anabolic agents (to build bone).
Major chemical classes under antiresorptive drugs are bisphosphonates, estrogen, selective estrogen receptor modulators (SERMs), biological, and calcitonin. In 2010, the FDA approved monoclonal antibody named Denosumab for the treatment of postmenopausal women who are at high risk of fractures. Teriparatide is a synthetic form of parathyroid hormone and is the only FDA-approved anabolic. Phosphate binding agents and dialysis are used in the treatment of hyperphosphatemia. There are three types of phosphate binders: calcium based binders, non-calcium based binders, non-metal based binders, and metal-based binders.
Aluminum and magnesium-based binders. Vitamin D analog is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. Management of secondary hyperparathyroidism in patients not yet on dialysis is done with calcitriol capsules and oral solution. Calcimimetic agent (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism in patients with CKD on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma. Apart from these disease specific agents, pain managing medications and several types of surgeries are driving the market.
Request to View ToC of the report -
Key players operating in the bone and mineral metabolism disorder treatment market are Eli Lilly and Company, F. Hoffmann-La Roche, Pfizer, Inc., Actavis plc, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Amgen, Inc., Merck & Co., Inc., and Novartis International AG.